THOUGHT LEADERS AND INNOVATORS came TOGETHER TO SHARE THEIR KNOWLEDGE, EXPERIENCE, RESEARCH, AND INSIGHTS ABOUT a.I.
Presented by alio
summit recap
summit SPEAKERS
Elizabeth Jennings has worked at the intersection of international investment and commercialization within healthcare for the last fifteen years, spanning 28 countries and all classes of complexity, building a reputation for strategic risk management for both investors and companies.She is currently the Vice President of Marketing for an Australian Stock Exchange-traded AI company, Echo IQ, focused on leveraging AI in a proprietary manner to change the way structural heart diseases are detected.
Elizabeth has been a commercial leader at four AI healthtech startups and has consulted and advised dozens around the globe. She also serves on the Board of Directors for the fastest-growing angel impact network in the US, SWAN Impact; has led the European Network of Research Innovation Centres and Hubs' healthcare portfolio in the US; and served on multiple international healthcare councils, federal early-stage grant review panels, and accelerators.
Prior to joining Echo IQ, Elizabeth was the Managing Partner of Venture Atlas Labs, a commercialization firm known for bringing innovative technologies to commercial success in some of the most challenging markets around the world on behalf of family offices, private equity, VCs, and government funds. Her recent book, US Digital Healthcare Procurement, was commissioned by the Ministry of Foreign Affairs of Denmark and is a leading resource for navigating the US healthcare landscape for international startups.
Previous roles have included leading innovation programs for foreign governments at the Global Innovation Lab at the University of Texas at Austin, commercial expansion for multiple large diagnostics corporations in the US and France, and upstream investments in neglected tropical disease research.
Mary Beth Chalk is the Co-founder and Chief Commercial Officer of BeeKeeperAI TM , creator of EscrowAI TM , a zero-trust, multi-party collaboration platform leveraging Azure confidential computing to enable end-to-end encryption for privacy protected information and the intellectual property of algorithm and analytic models. Mary Beth has over 25-years of creating and commercializing data-driven healthcare innovation.
Prior to BeeKeeperAI she led business development at the Center for Digital Health Innovation at UCSF where she secured over $50M in funding for innovation projects, including AI validation. Prior to UCSF, she was the Co-founder and Chief Engagement Officer for an AI platform spun out of Mass General Brigham delivering precision disease management coaching utilizing remote monitoring device data and social determinants of health.
During her tenure as the Chief Operating Officer of a mental health company she created and deployed the SIGNAL system (outcome prediction algorithms) utilized to inform and improve the effectiveness of psychotherapy.
David Kuraguntla, D.O. is the Co-Founder and CEO of Alio Medical. Dave received his master’s degree from Boston University and was a researcher at the National Institutes of Health. He then went to medical school on an Air Force scholarship.
He received his medical degree in osteopathic medicine (D.O.) and was preparing for a surgical residency when he experienced firsthand the need for better technological solutions for patients with chronic conditions. This experience lead Dave to start Alio, which has grown to become the best-in-class wearable system to remotely, non-invasively measure the function of the kidney, heart, and blood vessels.
The Alio SmartPatch synthesizes multiple, novel metrics to drive insights across cardiovascular and renal medicine, with special dedication to improving the lives of those living with chronic kidney disease (CKD).
Dr. Connor Glass is the Founder & CEO of Phantom Neuro which seeks to enable lifelike control of prosthetic limbs and exoskeletons for individuals with limb difference and beyond. Dr. Glass received his medical degree from the University of Oklahoma College of Medicine followed by a multi-year research fellowship in Plastic Surgery at Johns Hopkins University School of Medicine where he studied surgical interventions for peripheral nerve injury and advanced prosthesis control.
He is the primary inventor of a minimally invasive implantable muscle-machine interface which his company now seeks to commercialize. His company has raised nearly $10 million in venture capital. Dr. Glass has multiple publications on nerve injury and neuromuscular reconstructive surgery and co-authored a chapter in the Handbook of Neuroengineering.
He works on domestic and international efforts to advance amputation care and prosthetic outcomes, and his work has been featured in outlets such as the Wall Street Journal, Axios, and STAT.
Dr. Adam Hansen is an accomplished scientist and entrepreneur who has dedicated his career to relieving human suffering through the advancement of precision medicine. He founded and leads Geneial, a private exchange for genetic and patient-reported outcomes data. Less than two years after completion of his doctoral training, Dr. Hansen and team were awarded a $2.3M fast-track Small Business Innovation Research (SBIR) grant from the National Human Genome Research Institute (NHGRI). He serves as Principal Investigator (PI), Founder, and CEO at Geneial and is a co-inventor of three international patent applications (pending).
During his doctoral training at Baylor College of Medicine under Dr. Richard Gibbs at the Human Genome Sequencing Center, he led the discovery of 154 candidate genetic disorders through a genocentric, query-optimization strategy for exome sequencing data of over 18,000 individuals. Upon completion of his doctoral studies, Dr. Hansen was selected as a Biodesign Fellow at the Texas Medical Center Innovation Institute, where he expanded his knowledge of digital health, value-based-care, and new venture formation.
Dr. Hansen’s research interests are focused on identifying novel genetic causes of human disease through next-generation sequencing, elucidating the natural history of genetic disorders through registry design and patient-reported outcomes data, data standardization, Mendelian and population genetics, pharmacogenomics, and high-performance computing. He is passionate about leveraging AI to accelerate the pace of discovery, aligning incentives for data exchange, and enhancing protections for patient privacy and data ownership.
He received a Bachelor of Science in Bioinformatics from Brigham Young University with minors in Computer Science, Chinese, and Global Business & Literacy. He also studied abroad at Nanjing University, where he studied advanced Chinese Language and Literature, and is fluent in Mandarin. In his free time he volunteers to teach a weekly English as a Second Language (ESL) course. He serves on the industry advisory board for the University of Utah Department of Biomedical Informatics, and has been invited to speak on health equity, innovation, and the importance of character in leadership.
Dr. Ben Herndon, Chief Strategy Officer at KUNGFU.AI has over 30 years of experience in organizational transformation and cognition. He has worked with organizations ranging from small startups to the U.S. Internal Revenue Service, where he was the first Chief Research and Analytics Officer leading the operationalization of AI/ML/DS at scale in tax collection.
Ben holds a Ph.D. in Organizational Cognition from the University of Texas at Austin McCombs School of Business and was a research professor at the Georgia Institute of Technology.
In his most recent role, he was Director of AI Strategy for Vista Equity Partners. He holds a B.S. in political science from Harvard University.
Ganesh Padmanabhan is the CEO & founder of Autonomize AI, a technology company applying Trusted Generative AI to healthcare and lifesciences. Autonomize’s AI products organize, contextualize and summarize unstructured data so healthcare knowledge workers can make data-driven decisions, to improve patient outcomes. Autonomize AI is a founding member of CancerX, US President Biden’s Cancer Moonshot initiative.
He is also the Founder & Chief Creator of Stories in AI, an edu-tainment venture. He previously co-founded and scaled Molecula Corp, a data management company, and led growth and commercial at CognitiveScale, Inc, an Enterprise AI company. Prior to that he spent a 15 year career spanning Dell Technologies and Intel Corp.
A frequent keynote speaker, he is published at Forbes, Business Insider, Fast Company and other publications and was honored by the Enterprise Management 360 as one of the top 10 tech experts revolutionizing AI. Ganesh holds a bachelor’s degree in Mechanical Engineering from University of Calicut, India, and an MBA from McCombs School at the University of Texas Austin.